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Abstract
Alcoholic liver disease (ALD), a leading cause of chronic liver injury worldwide, comprises a 
range of disorders including simple steatosis, steatohepatitis, cirrhosis, and hepatocellular 
carcinoma. Over the last five decades, many animal models that have been useful for the study of 
ALD pathogenesis have been developed. Recently, a chronic-plus-binge ethanol feeding model 
was reported. This model induces significant steatosis, hepatic neutrophil infiltration, and liver 
injury. A clinically relevant model of high-fat diet feeding plus binge ethanol was also developed, 
which highlights the risk of excessive binge drinking in obese/overweight individuals. All of these 
models recapitulate some features of the different stages of ALD and have been widely used by 
many investigators to study the pathogenesis of ALD and test therapeutic drugs/components. 
However, these models are somewhat variable, depending on mouse genetic background, ethanol 
dose, and animal facility environment. This review focuses on these models and discusses these 
variations and some methods to improve the feeding protocol. The pathogenesis, clinical 
relevance, and translational studies of these models are also discussed.
Excessive alcohol consumption is a leading cause of chronic liver diseases worldwide 1 and 
causes a broad spectrum of liver disorders ranging from simple steatosis to severe forms of 
liver injury including steatohepatitis, fibrosis/cirrhosis, and hepatocellular carcinoma2, 3. 
Over the last five decades, investigators have been actively exploring animal models for 
alcoholic liver disease (ALD), studying its pathogenesis and searching for therapeutic drugs 
for the treatment of ALD. However, currently, there are still no FDA-approved drugs for 
ALD treatment, and no animal models represent the full spectrum of human ALD4, 5. Most 
Corresponding author: Dr. Bin Gao (bgao@mail.nih.gov), NIAAA/NIH, 5625 Fishers Lane, Bethesda, MD 20892. 
No conflicts of interest exist for any of the authors.
HHS Public Access
Author manuscript
Gene Expr. Author manuscript; available in PMC 2017 July 07.
Published in final edited form as:
Gene Expr. 2017 July 07; 17(3): 173–186. doi:10.3727/105221617X695519.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
animal models that involve chronic alcohol feeding develop steatosis but demonstrate low or 
little neutrophil infiltration, whereas hepatic neutrophil infiltration is a hallmark of alcoholic 
steatohepatitis in human patients.
Accumulating evidence suggests that drinking patterns and obesity have significant impacts 
on the progression of alcoholic liver disease (ALD). For example, recent drinking and binge 
drinking are associated with a high risk of the development of severe forms of ALD6. 
Obesity is another risk factor that exacerbates ALD as documented in clinical studies7–9. 
Furthermore, in a large cohort of patients with alcoholic hepatitis, body mass index is an 
independent predictor of the disease severity10. Based on these observations, we developed 
two murine models: chronic-plus-binge ethanol feeding and high-fat diet (HFD)-plus-binge 
ethanol challenge. Since it was published in 201011, 12, the chronic-plus-binge model has 
been widely used by many investigators, and many novel mechanisms underlying liver 
inflammation and injury in this model have been revealed. Recently, the chronic-plus-binge 
ethanol mouse model has also been used to examine other organ damage such as the heart13, 
pancreas14, and adipose tissues15. In addition, this model was also established in rats16, 17. 
The HFD-plus-binge ethanol model was published in 201518. This model is clinically 
relevant and highlights the risk of liver injury in even one excessive binge drinking session 
in obese/overweight individuals. Using this clinically relevant model, we have identified 
several novel mechanisms that play important roles in inducing neutrophilia and liver injury 
post HFD-plus-binge ethanol challenge.
Both the chronic-plus-binge and HFD-plus-binge ethanol feeding models represent only the 
early stages of steatohepatitis, whereas a recently developed hybrid model induces a more 
severe form of steatohepatitis and liver injury. This hybrid model was established by 
allowing ad lib feeding of a solid Western diet followed by intragastric infusion of an 
ethanol liquid diet with addition of a weekly binge of ethanol19. This model reproduces 
some features of chronic alcoholic steatohepatitis and early alcoholic hepatitis (AH)19. The 
details of this hybrid model have previously been discussed 19, 20 and will not be described 
here. In this article, we discuss several factors that affect chronic-plus-binge and HFD-plus-
binge ethanol-induced liver injury and the mechanisms that underlie the liver injury in these 
models. We also discuss some translational studies of chronic-plus-recent binge drinking in 
patients with excessive alcohol use (EAU).
Factors that affect chronic-plus-one-binge ethanol feeding-induced liver 
injury
A short-term (10-day)-plus-binge ethanol feeding model was first reported in 201011, 12. 
This protocol induces significant hepatic steatosis with substantial increase in the levels of 
ALT and AST. Later, long-term (up to 12-week)-plus-one binge or multiple binges of 
ethanol feeding were also developed21, which induce more severe phenotypes of 
steatohepatitis compared to the short-term (10-day)-plus-binge ethanol model. Over the last 
five years, we have noticed many factors that may affect the outcomes of liver injury and 
inflammation in the chronic-plus-binge ethanol feeding model. These factors are discussed 
below, and some potential improvements are also described.
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Genetic background of mice
Inbred C57BL/6 mice are known to show higher voluntary alcohol consumption than other 
strains such as BALB/c and DBA/J22. Indeed, we found that chronic-plus-binge ethanol 
feeding works well in both C57BL/6J and C57BL/6N mice but not in BALB/c and DBA/J 
mice (both BALB/c and DBA/J mice are reluctant to eat the ethanol diet). Interestingly, 
chronic ethanol feeding for 4 weeks in C57BL/6J mice can result in a mortality rate up to 
50%, but no mortality was observed in C57BL6/N mice (Figure 1A). Therefore, we have 
often used C57BL/6J mice for the short-term (10-day)-plus-one binge ethanol feeding 
model. C57BL6/N mice are used for both short- (10 days) and long-term (up to 12 weeks)-
plus-one binge or multiple binges of ethanol feeding. If the genetically modified mice were 
not on a C57BL/6 background, we backcrossed them into either C57BL6/N or C57BL6/J 
background for up to 10 generations. Heterozygous breeding was often performed, and 
littermate wild-type controls were used for the control group.
Male and female mice
It has been documented that female rodents (rats and mice) are more susceptible to chronic 
alcohol-induced liver injury than males23. A recent study also compared chronic-plus-binge 
ethanol-induced liver injury in male and female mice, and these data revealed that the 
chronic-plus-binge ethanol challenge induced a greater degree of adipose tissue 
inflammation and liver injury in female than in male mice despite lower levels of alcohol 
consumption15. In our laboratory, we have used both male and female C57BL/6 mice for 
chronic-plus-binge ethanol feeding but prefer to use female mice for the short-term (10-d)-
plus-one binge ethanol feeding and male mice for the long-term (up to 12-week)-plus-one or 
multiple binges of ethanol feeding.
Animal facility environment
We observed that the C57BL/6J mice, which were purchased from the Jackson (Jax) 
laboratory and housed in our facility for one or two weeks, were sensitive to chronic-plus-
binge ethanol-induced liver injury (with the average peak of serum ALT levels ~ 250 IU/
L)24. Interestingly, after being housed in the NIAAA animal facility for a few months, the 
C57BL/6J mice became less sensitive to the chronic-plus-binge ethanol-induced liver injury 
(with average peak of serum ALT levels ~100 IU/L). The reasons for this difference are 
probably the differences in the facility environment and conditions between the Jax 
laboratory and the NIAAA animal facility. For example, Jax laboratory animal facility is a 
‘barrier’ facility, whereas the NIAAA animal facility and most NIH intramural program 
animal facilities have a variety of “acceptable pathogens” https://collab.niaaa.nih.gov/
Intramural/OLAS/Shared%20Documents/Acceptable%20'Pathogen'%20List.pdf. The table 
below outlines the environmental differences between the two facilities.
Jax lab animal facility NIAAA animal facility
Sterilized autoclaved or irradiated feed Non-sterilized or irradiated feed
Acidified drinking water (pH 2.5 to 3) Tap water (pH 6.5 to 8.5)
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Jax lab animal facility NIAAA animal facility
Steam-sterilized bedding Non-sterilized bedding
Mouse transfer by disinfected forceps Mouse transfer by gloved hands
Strict barrier sanitation of caging equipment through 
tunnel washers
Caging equipment goes through the industrial washer. 
Racks go through the rack washer.
Restricted entry Limited access
Room temperature
Many investigators have observed various percentages of mortality in C57BL/6J mice after 
chronic feeding with Lieber-Decali diet containing 5% ethanol for more than 4 weeks. 
However, this mortality was not observed in C57BL/6N mice. Alcohol consumption is 
known to cause hypothermia in mice. To determine whether a low room temperature 
contributes to the mortality in C57BL/6J mice, we chronically fed C57BL/6J mice in rooms 
with three different temperatures (72°±1° F; 74°±1° F; and 76°±1° F). The mortality in 
C57BL/6J mice that were housed at 72°±1° F room temperature (NIAAA animal facility 
holding rooms are set as alarm range is 72°±3° F. Holding rooms are running at 72°±1° F) 
after 4 weeks of ethanol feeding was 20–50%. However, only 1 of 8 mice died in the 8-week 
ethanol-fed C57BL/6J mouse group when the room temperature was set at 74°±1° F, and no 
morality was observed when the room temperature was set at 76°±1° F (Figure 1B). 
Interestingly, in the rooms with higher temperatures where no mortality was observed, the 
serum ALT and AST levels were lower than those in the rooms with lower temperatures 
(data not shown).
Doses of ethanol
In our original protocol, we used a liquid diet containing 5% ethanol and mice were gavaged 
with 5 g/kg ethanol12. As mentioned above, mice may become less sensitive to liver injury 
(as indicated by a less pronounced elevation in serum ALT and AST levels) when they are 
housed in the NIAAA facility or when they have a mixed background. To achieve a higher 
level of liver injury, we increased the concentration of ethanol in the liquid diet to 5.5–6% or 
gavaged mice with 6 g/kg of ethanol.
Mortality
In addition to housing mice in the low temperature environment, improper technique during 
the oral gavage is another leading cause of mortality. In general, mice should be gently 
restrained and the head should be immobilized. The appropriate length of the gavage needle 
should be used and carefully passed along the side of the mouth. Improper technique may 
result in the injection of ethanol into the trachea and lungs during gavage. Furthermore, 
excessive force in advancing the gavage needle may cause esophageal or tracheal 
penetration12. The mortality rates in the chronic-plus-binge models in male C57BL/6N mice 
in our laboratory are shown in Figure 1C.
Gao et al. Page 4
Gene Expr. Author manuscript; available in PMC 2017 July 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Factors that affect HFD-plus-one binge ethanol feeding-induced liver injury
Although obesity and alcohol drinking are known to synergistically exacerbate the 
progression of liver disease, there were no good models to mimic this condition. One of the 
major obstacles was that ad libitum feeding of mice with ethanol in drinking water or in 
liquid diet markedly reduced the HFD intake and body weight unless the mice were 
subjected to intragastric overfeeding with the HFD and alcohol25. Recently, we developed a 
model in which mice were fed with HFD first to induce overweight/obesity, which was then 
followed by oral gavage of a single dose of ethanol18. Our data revealed that chronic HFD 
feeding (3 months of HFD) in male C57BL/6J mice caused a moderate elevation of serum 
ALT (approximately 100–200 IU/L). While a single dose of ethanol (5 g/kg) gavage in 
chow-fed 12-week-old male C57BL/6J mice did not cause significant increases in the serum 
ALT and AST levels, a single dose ethanol gavage (5 g/kg) caused a significant increase in 
the serum ALT levels to approximately 150 IU/L and 800 IU/L in male C57BL/6J mice that 
were fed with HFD for 3 days and 3 months, respectively18. In addition to highly elevated 
serum ALT and AST levels, significant neutrophilia, hepatic neutrophil infiltration, and liver 
inflammation were other important features that were observed in these mice with HFD-
plus-binge ethanol challenge. In conclusion, an acute binge of a single dose of ethanol 
causes severe acute steatohepatitis in obese mice, and this is a clinically relevant model for 
studies of the interaction of obesity with binge alcohol drinking. During our study, we 
noticed several factors that affected the outcome of the HFD-plus-binge ethanol feeding 
model, which are discussed below.
Genetic background and gender of mice
Male C57BL/6 mice are the most susceptible strain for the development of HFD-induced 
obesity and insulin resistance and are the most common strain used in the study of metabolic 
disease. We have tested the 3-month-HFD-plus-binge ethanol feeding model in several 
strains and found that HFD-plus-binge ethanol feeding induced higher levels of serum ALT 
and AST in male C57BL/6 mice than in male BALB/c and DBA mice. The underlying 
mechanisms probably involve the fact that male C57BL/6 mice gained the greatest body 
weight after HFD feeding among these strains. In addition, we found that female C57BL/6 
mice were much less sensitive to the HFD-plus-binge ethanol feeding-induced liver injury 
than the male counterparts, probably because female C57BL/6 mice gained much less body 
weight post HFD feeding. Interestingly, we observed that the HFD-plus-one binge ethanol 
challenge induced greater serum ALT levels in male C57BL/6N mice than in C57BL/6J 
mice.
Animal facility environment
Any environmental factors that alter the weight gain may significantly affect the outcome of 
HFD-plus-binge ethanol-induced liver injury. For example, stress significantly affects food 
intake and weight gain during HFD feeding. Stresses to the mice should be avoided during 
HFD feeding. We tried not to disturb or only to minimally disturb these mice during the 
HFD feeding. Regrouping male mice from different litters in the same cage, which increases 
the stress level, is not recommended before HFD feeding. For example, 8- to 12-week-old 
male C57BL6 mice usually gained approximately 2–3 grams after the first 3 days of HFD 
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feeding (HFD: 60% fat), and the 3-day HFD-fed mice usually had serum ALT levels of 
approximately 150 U/L after one binge of 5 g/kg ethanol. However, mice under stress 
conditions such as being separated or placed in mixed housing before feeding gained less 
than 1 g after 3 days of HFD feeding and they demonstrated minimally elevated serum ALT 
and AST after the ethanol binge.
Doses of ethanol
In our original protocol, we gavaged the HFD-fed mice with a single dose of 5 g/kg 
ethanol18 and observed approximately 10–15% mortality especially in the HFD-fed mice 
with body weights over 55 grams. For mice over 60 grams, we usually gavaged with a single 
dose of 4 g/kg ethanol. However, gavage with a lower dose of ethanol may cause less liver 
damage.
HFD composition
The type of fat (saturated vs. unsaturated) may also affect the outcome of HFD-plus-binge 
ethanol feeding. Saturated fat has been shown to be protective against ALD, while 
unsaturated fat is deleterious for ALD26. We used a HFD in which 60% of the calories were 
derived from fat (catalog no. D12492; Research Diet, New Brunswick, NJ) in our HFD-plus-
binge ethanol model, and this diet is working well in this model. We have not tested any 
diets with other types or proportions of fat in this model.
Chronic-plus-multiple binges of ethanol model
We performed two models of chronic-plus-multiple binges of ethanol. First, mice were 
subjected to chronic ethanol feeding up to 12 weeks, followed by three ethanol binges on 
consecutive days, and mice were euthanized at various time points after the last gavage. 
Second, mice were chronically fed an ethanol diet plus binge ethanol twice a week 
throughout the chronic feeding period up to 12 weeks, and mice were euthanized at various 
time points after the last gavage. The mice that were subjected to these chronic-plus-multiple 
binges of ethanol models developed some degrees of hepatic inflammation and liver fibrosis 
but surprisingly had lower serum ALT and AST levels than those in the chronic (up to 12 
weeks)-plus-one binge-challenged mice21.
Chronic-plus-multiple binges caused approximately 10–20% mortality with most of the 
mortality being observed after the second or third binge. One way to reduce the mortality is 
to reduce the dosage of ethanol during the initial binges (e.g., binge of 4 g/kg ethanol for 
first three binges and 5 g/kg ethanol for the following binges).
HFD-plus-multiple binges of ethanol feeding models
We also performed HFD-plus-multiple binges of ethanol feeding and encountered two 
challenges, including loss of body weight and increasing in mortality. Gavage with 4 or 5 
g/kg ethanol significantly reduced the intake of HFD in mice, which resulted in significantly 
lower body weights in HFD-plus-multiple binges-fed mice than in the mice fed the HFD 
alone. Mortality is another problem with >50% death observed in HFD-plus-multiple binge-
fed mice with binge of 5 g/kg ethanol. The C57BL/6N mice had >80% mortality after the 
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first two binges, whereas the C57BL/6J mice had a better survival rate. After ethanol gavage, 
the HFD-fed C57BL/6J mice began to lose body weight but later regained body weight to 
the initial level. However, the mortality rate is also dependent on the skills of the person 
administering the gavage and animal care. Although we observed significant liver injury and 
inflammation with obvious fibrosis in mice subjected to the HFD-plus-multiple ethanol 
binges, this model is challenging to establish. The C57BL/6J mice had higher degrees of 
fibrosis than the C57BL/6N mice after the HFD-plus-multiple binges procedures.
New insights into the underlying mechanisms of chronic-plus-binge and 
HFD-plus-binge ethanol feeding-induced liver injury
Over the last five years, using the chronic-plus-binge or HFD-plus-binge ethanol feeding 
models, investigators have identified various mediators that regulate liver inflammation and 
injury in these models. These mediators are summarized as follows.
Neutrophils
One of the key features of alcoholic steatohepatitis in patients is the infiltration of 
neutrophils in the liver27. However, few neutrophils are found in the livers of mice that are 
chronically fed an ethanol diet. In contrast, significant neutrophils are observed in the livers 
of mice that are challenged with chronic-plus-binge ethanol feeding or HFD-plus-binge 
ethanol feeding18, 21, 28. Such hepatic neutrophil infiltration is likely caused by several 
mediators including E-selectin, CXCL1, and TLR9.
Real-time PCR analyses showed that among the various inflammatory mediators that 
promote neutrophil infiltration, E-selectin had the highest fold upregulation in the liver after 
chronic-plus-binge ethanol challenge28. Deletion of the E-selectin gene reduced the hepatic 
neutrophil infiltration and liver injury in this model, suggesting that E-selectin plays an 
important role in promoting hepatic neutrophil infiltration28. Interestingly, in the HFD-plus-
binge ethanol feeding model, among the various inflammatory mediators that promote 
neutrophil infiltration, hepatic CXCL1 rather than E-selection had the highest fold 
upregulation18. CXCL1 is one of the most important chemokines for neutrophil recruitment 
in mice. Indeed, blockade of CXCL1 via deletion of the Cxcl1 gene or treatment with an 
anti-CXCL1 antibody or an IL-8 receptor inhibitor markedly prevented the hepatic 
neutrophil infiltration and liver injury post chronic-plus-binge or HFD-plus-binge ethanol 
challenge18, 29. The dramatic upregulation of Cxcl1 in the liver post HFD-plus-binge ethanol 
exposure is likely due to the significant elevation of the free fatty acids that directly induce 
hepatic Cxcl1 gene expression18. Moreover, a recent study reported that activation of the 
TLR2- and TLR9-dependent MyD88-dependent pathway contributed to CXCL1 production 
by hepatocytes and hepatic stellate cells, which subsequently promoted neutrophil 
infiltration and liver injury post chronic-plus-binge ethanol feeding30. In addition, 
lipocalin-2 seems to contribute to the hepatic neutrophil infiltration, steatosis, and liver 
injury induced by chronic alcohol feeding31, 32 or acute ethanol gavage32. Osteopontin 
(OPN), one of the most upregulated genes in human AH, contributes to the hepatic 
neutrophil infiltration and liver injury induced by short-term chronic-plus-binge ethanol 
feeding33 but seems to have a protective role in a mouse model of severe alcoholic hepatitis 
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induced by intragastric feeding of alcohol and a HFD diet with a weekly alcohol binge19. 
Another study suggested that OPN may protect against chronic alcoholic liver injury by 
blocking the gut-derived LPS and TNF-α in the liver34. These discrepancies could be 
explained, in part, by differences in the models being studied (i.e., varying degrees of 
severity, duration, gender) and possibly by the different forms of OPNs (i.e., the intracellular 
OPN isoform [iOPN] and the extracellular/soluble cytokine [sOPN])35.
Additional evidence for an important role of neutrophils in alcoholic liver injury is that the 
genetic deletion of miR-223, one of the most abundant miRNAs in neutrophils36, enhanced 
neutrophil functions and liver injury, whereas deletion of phagocytic oxidase (phox) p47phox 
abolished reactive oxygen species (ROS) production by the neutrophils and ameliorated the 
liver injury induced by chronic-plus-binge ethanol feeding37, 38. Mechanistic studies 
revealed that miR-223 directly inhibited IL-6 expression and subsequently inhibited p47phox 
expression in neutrophils, thereby attenuating hepatic neutrophil activation and liver 
injury37, 38.
Because blockade of E-selectin or CXCL1 not only prevented hepatic neutrophil infiltration 
but also ameliorated the liver injury induced by chronic-plus-binge or HFD-plus-binge 
ethanol exposure18, 28, it is plausible to speculate that neutrophils likely contribute to the 
hepatocellular damage in these models. Finally, more conclusive evidence for an important 
role of neutrophils in chronic-plus-binge ethanol-induced liver injury was given by the result 
that depletion of neutrophils using a neutralizing antibody ameliorates liver injury in this 
model18, 28. Although we provided convincing evidence that neutrophils contribute to 
hepatocellular damage in the mild liver injury in these models, neutrophils likely play both 
detrimental and beneficial roles in the pathogenesis of severe forms of ALD, such as 
promoting hepatotoxicity, protecting against bacterial infection, and promoting liver 
regeneration39–41.
Kupffer cells/macrophages
Hepatic Kupffer cells/macrophages are activated after chronic ethanol consumption in mice 
and play an important role in the pathogenesis of ALD27, 42. Depletion of Kupffer cells/
macrophages also reduced the chronic-plus-binge ethanol-induced liver injury and 
inflammation, which suggests that these cells also contribute to the pathogenesis in this 
model43. Mechanistic studies suggest that Kupffer cells/macrophages produce IL-1β and 
subsequently recruit/activate hepatic iNKT cells43. Activated NKT cells promote hepatic 
neutrophil infiltration, liver inflammation and alcoholic liver injury43. Interestingly, chronic 
ethanol feeding increases the number of hepatic F4/80+ Kupffer cells/macrophages in mice, 
whereas an acute binge of ethanol reduces these cells in the liver28. Therefore, the changes 
in the number of hepatic F4/80+ cells post chronic-plus-binge ethanol feeding are affected 
by the length of the ethanol feeding, the doses of ethanol feeding and binge, and the number 
of binges.
Natural Killer T (NKT) cells
NKT cells are enriched among the liver lymphocytes and play important roles in the 
pathogenesis of liver diseases44, 45. Several recent studies have revealed that chronic-plus-
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binge ethanol feeding synergistically increased the number of hepatic iNKT cells and 
induced their activation compared with chronic feeding or binges alone43, 46, 47. iNKT cell-
deficient mice were protected from the chronic-plus-binge ethanol-induced hepatic 
neutrophil infiltration and liver injury43, 46, 47. Mechanistic studies have suggested that 
chronic-plus-binge ethanol feeding activates hepatic iNKT cells, which play a critical role in 
the development of early alcoholic liver injury, in part by releasing mediators that recruit 
neutrophils to the liver43, 46, 47, and thus, iNKT cells represent a potential therapeutic target 
for the treatment of ALD.
Cell death and autophagy
Cell death through apoptosis as well as necrosis/necroptosis plays an important role in the 
pathogenesis of ALD48–53. Receptor-interacting protein kinase (RIP) 3 has emerged as a 
critical regulator of programmed necrosis/necroptosis and is implicated in a variety of 
pathological conditions, including chronic ethanol feeding-induced liver injury53. Recently, 
the roles of RIP3 in chronic-plus-binge ethanol-induced hepatotoxicity were also examined. 
Chronic-plus-binge ethanol feeding markedly upregulated hepatic RIP3 protein but not RIP1 
protein expression54. This upregulation of hepatic RIP3 protein was due to impaired hepatic 
proteasome function post alcohol exposure54. Genetic deletion of the Rip3 gene reduced the 
chronic-plus-binge ethanol-induced elevation of serum ALT activity and hepatic steatosis but 
did not affect hepatic neutrophil infiltration54. Thus, hepatic accumulation of RIP3 protein 
results in necroptosis and steatosis post chronic-plus-binge ethanol challenge54.
Autophagy is a critical intracellular degradation pathway that promotes the trafficking of 
long-lived proteins and cellular organelles to the lysosome for degradation to maintain 
cellular homeostasis. Although autophagy has been generally believed to serve a beneficial 
function in alcoholic liver injury by removing damaged mitochondria and lipid droplets, the 
results regarding the role of autophagy in the pathogenesis of ALD have been controversial 
due to the complexity of the different ALD models, lack of reliable markers, and the 
difficulty of monitoring autophagic flux55–59. Several recent studies have suggested that 
Parkin-mediated mitophagy and hypoxia-inducing factor-1α-dependent FoxO3a-mediated 
hepatic autophagy in hepatocytes protect against chronic-plus-binge ethanol-induced liver 
injury60, 61. Autophagy in myeloid cells has also been suggested to play a protective role in 
mediating the anti-inflammatory and anti-steatogenic functions of cannabinoid receptor 2 in 
ALD induced by chronic-plus-binge ethanol feeding62.
FSP-27/CIDEC
Microarray analyses have revealed that various genes in the liver were highly upregulated in 
mice post chronic-plus-binge ethanol feeding, and many of these genes are also markedly 
elevated in human alcoholic hepatitis liver samples21. Among these highly up-regulated 
genes, the Fsp27 gene was up-regulated by 13 folds in chronic-plus-binge ethanol-fed 
mice21. The mouse Fsp27 gene is the homolog of the human DFF45-like effector-C 
(CIDEC), a member of the CIDE family of proteins, which includes CIDEA, CIDEB, and 
CIDEC (human)/FSP27 (mice). Interestingly, hepatic expression of CIDEC was also 
markedly up-regulated in human alcoholic hepatitis but only slightly elevated in human 
alcoholic cirrhosis21. In mice, the Fsp27 gene has two isoforms, Fsp27α and Fsp27β, and 
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Fsp27β is the predominant form expressed in the liver63, 64. The expression of both Fsp27α 
and Fsp27β mRNA in the liver is highly upregulated in mice post chronic-plus-binge ethanol 
feeding, and this upregulation is due to the activation of the endoplasmic reticulum (ER) by 
ethanol21. Inhibition of the Fsp27 gene by Ad-Fsp27shRNA or hepatocyte-specific Fsp27 
deletion markedly ameliorates chronic-plus-binge ethanol-induced liver injury, which 
suggests that FSP27 plays important roles in promoting alcoholic steatohepatitis by 
stimulating fat droplet formation and inducing mitochondrial injury21. In addition, clinical 
data have revealed that the upregulation of hepatic CIDEC is closely associated with the 
severity of hepatic steatosis as well as the disease severity (such as MELD and ABIC scores) 
in patients with AH. Hepatic CIDEC mRNA levels are also positively correlated with the 
hepatic venous pressure gradient and are an independent predictor for 90-day mortality in 
patients with AH21, suggesting that CIEDC contributes to the pathogenesis of human AH.
FSP-27/CIDEC is known to play an important role in promoting nonalcoholic 
steatohepatitis64, 65. Hepatic Fsp27 expression is elevated in HFD-fed mice and is further 
upregulated in these mice after an ethanol binge66. Interestingly, the elevated FSP27 plays a 
critical role in inducing steatosis and liver fibrosis induced by HFD-plus-binge ethanol 
feeding but did not affect hepatic neutrophil infiltration in this model66.
Sirtuin 1 (SIRT1)
SIRT1 is an NAD-dependent deacetylase that is able to catalyze lysine substrate 
deacetylation/deacylation at specific sites and thus plays critical roles in the control of 
metabolic stress, caloric restriction, and cancer. Using the chronic-plus-binge ethanol 
feeding model, several investigators have demonstrated that SIRT1 in hepatocytes 
ameliorates hepatic steatosis and injury67 and that SIRT1 in hepatic stellate cells (HSCs) 
attenuates HSC activation via the downregulation of platelet-derived growth factor receptor 
alpha (PDGFRα) and c-Myc68. Furthermore, SIRT1 expression in the liver is downregulated 
in aged and middle-aged mice, and such downregulation is probably one of the important 
mechanisms that contribute to the increased alcoholic liver injury in middle-aged and aged 
mice68. Finally, emerging evidence suggests that lipin-1 is a crucial downstream regulator of 
the SIRT1-AMPK signaling system that plays complex cell-specific roles in the 
pathogenesis of ALD69–71.
Others
In addition to the mediators mentioned above, several other factors that regulate lipid 
metabolism have also been shown to play important roles in the pathogenesis of chronic-
plus-binge ethanol-induced liver damage. For example, fibroblast growth factor 21 (FGF21) 
is an FGF family member that is produced by the liver and other metabolic tissues and plays 
an important role in regulating glucose and lipid metabolism72–74. Recent studies reported 
that chronic-plus-binge ethanol feeding or chronic ethanol feeding markedly upregulates 
FGF21 levels in the liver and serum, with much higher levels in chronic-plus-binge ethanol-
fed groups than in chronically ethanol-fed mice75, 76. Interestingly, FGF21 knockout mice 
were protected from chronic-plus-binge ethanol-induced liver injury but were more 
susceptible to chronic ethanol feeding-induced hepatotoxicity75. The detrimental roles of 
highly elevated FGF21 in the chronic-plus-binge ethanol-induced liver injury are likely due 
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to FGF21-mediated induction of systemic catecholamines, which promote adipose tissue 
lipolysis and subsequently induce lipotoxicity in the liver76. The protective functions of 
FGF21 in chronically ethanol-fed mice were due to FGF-induced inhibition of the 
expression of genes associated with lipogenesis and stimulation of those associated with 
oxidation in the liver75.
Stearoyl-CoA desaturase-1 (SCD1) is a delta-9 fatty acid desaturase that promotes the 
synthesis of mono-unsaturated fatty acids and has been found to play an important role in 
the development of steatosis and liver injury induced by chronic-plus-binge ethanol 
feeding77. Carboxylesterase 1 (CES1), a drug-metabolizing enzyme, has been shown to play 
an important role in the control of lipid metabolism78. Recent studies suggest that CES1 
plays an important role in protecting against chronic-plus-binge ethanol-induced liver injury 
via the inhibition of acetaldehyde production, ROS, and mitochondrial dysfunction79. 
Oxidized linoleic acid metabolites (OXLAMs), endogenous ligands for transient receptor 
potential vanilloid 1 (TRPV1), play a critical role in the development/progression of ALD. 
Using a chronic-plus-binge ethanol feeding model, Liu et al recently demonstrated that 
TRPV1-OXLAM interactions play an important role in promoting alcoholic liver 
inflammation and injury, which suggests an important role for dietary lipids in the 
pathogenesis of ALD80. The small heterodimer partner (SHP, NROB2) is a member of the 
nuclear receptor superfamily that functions as a transcriptional repressor and is a critical 
regulator of lipid metabolism81. The role of SHP in the pathogenesis of ALD has been 
extensively investigated in the chronic-plus-binge ethanol feeding model by several 
groups82–85. The data from these studies suggest that SHP plays a complex role in the 
pathogenesis of ALD via the regulation of ER stress, homocysteine metabolism, hepatic 
circadian clock, and ethanol catabolism82–85. In addition to lipids, glycogen, which is 
another form of energy storage in the liver, also has an important role in the control of 
chronic-plus-binge ethanol-induced liver injury via the regulation of lipid metabolism86.
The gut microbiota, which plays an important role in the pathogenesis of ALD87–89, has 
been examined in mouse models of chronic ALD but not in the chronic-plus-binge ethanol 
feeding model. One recent study examined the role of immunoglobulin A (IgA) in chronic-
plus-binge ethanol-induced liver injury90. Secretory IgA in the intestine prevents bacterial 
translocation by binding to the bacteria. However, surprisingly, the degree of liver damage in 
the IgA-deficient mice was similar to that of wild-type mice after chronic or chronic-plus-
binge ethanol challenge90. IgA-deficiency in mice is associated with an increased level of 
intestinal IgM that can limit bacterial translocation post ethanol challenge, which may 
compensate for the IgA deficiency and ameliorate ALD90. Spleen tyrosine kinase (SYK), a 
nonreceptor tyrosine kinase, plays a critical role in the pathogenesis of ALD by regulating 
multiple pro-inflammatory signaling pathways. Chronic-plus-binge ethanol exposure 
induces hepatic SYK activation in both hepatocytes and immune cells, and this activation 
seems to promote the inflammatory response and subsequently exacerbate liver injury51. 
FAT10, which belongs to the ubiquitin-like modifier (ULM) family, plays an important role 
in the control of protein degradation. Chronic-plus-binge ethanol feeding induces a 
reciprocal regulation of FAT10 and 4-hydroxynonenal (4-HNE) levels in hepatocytes, which 
stabilizes the oxidatively modified proteins and exacerbates liver injury91.
Gao et al. Page 11
Gene Expr. Author manuscript; available in PMC 2017 July 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Application of chronic-plus-binge ethanol model in testing therapeutic 
targets in preclinical studies
Over the last several years, the chronic-plus-binge ethanol feeding model has been used to 
examine several potential therapeutic targets for the treatment of ALD. Interleukin-22 
(IL-22), a key cytokine for hepatocyte survival and regeneration92, was the first drug to be 
tested in the chronic-plus-binge ethanol feeding model11. It was shown that treatment with 
IL-22 markedly ameliorated the steatosis and liver injury post chronic-plus-binge ethanol 
challenge11. Based on these promising preclinical data, IL-22 is currently being evaluated in 
a clinical trial for the treatment of patients with severe alcoholic hepatitis (Clinicaltrial.gov 
NCT02655510)93. IL-1 is an important constituent of the inflammasome, which plays a 
critical role in promoting alcoholic liver injury, and IL-1R antagonists have been tested in a 
modified mouse model of chronic-plus-binge ethanol feeding94, 95. The results from these 
studies revealed that blockade of IL-1 signaling ameliorated alcoholic liver inflammation 
and injury, and a clinical trial using an IL-1R blocker for the treatment of patients with 
severe AH is currently in progress (Clinicaltrial.gov NCT01809132)94, 95. Heat shock 
protein 90 (hsp90) is activated in human ALD and animal models of ALD. Inhibition of 
hsp90 by 17-dimethylamino-ethylamino-17-demethoxygeldanamycin ameliorated the 
steatosis and liver inflammation induced by chronic-plus-binge ethanol feeding, which 
suggests that hsp90 is a promising therapeutic target for the treatment of ALD96. More 
recently, the chronic-plus-binge ethanol feeding model has also been used to test the 
therapeutic potential of many drugs/compounds, including a CB2 agonist62, betulin (a 
triterpene from the bark of Betula platyphylla Suk)97, luteolin (a flavonoid)98, Lactobacillus 
rhamnosus GG99, Korean Red Ginseng100, glycycoumarin (a representative coumarin from 
traditional Chinese Medicine licorice)101, flaxseed oil enriched in α-linolenic acid (a plant-
derived n-3 polyunsaturated fatty acid)102, thymoquinone (a biologically active compound 
isolated from the seeds of Nigella sativa L.)103, and β-caryophyllene (BCP: a plant-derived 
FDA-approved food additive with anti-inflammatory properties)104. The data from these 
studies revealed that treatment with all of these components ameliorated the chronic-plus-
binge alcohol-induced liver inflammation and steatosis in mice. Because the chronic-plus-
binge ethanol feeding model represents the early stages of alcoholic steatohepatitis, further 
studies will be required to determine whether these components have beneficial effects for 
treatment of patients with severe ALD.
Translational studies of chronic-plus-binge and HFD-plus-binge ethanol 
feeding-induced liver injury in patients
The data from the studies of chronic-plus-binge ethanol feeding models suggest that 
drinking patterns (e.g., chronic, binge, and chronic-plus-binge) markedly affect liver injury 
and inflammation. For example, only chronic-plus-binge ethanol feeding markedly induced 
neutrophilia, hepatic neutrophil infiltration and injury, whereas chronic or binge ethanol 
challenge alone had less effects28, 37. The drinking patterns in humans are much more 
complex, which likely has a significant impact on the progression of ALD, but how the 
effects occur remains largely unknown. Recently, we studied 300 excessive alcohol users 
(EAUs) and stratified them into two groups including EAUs with recent drinking and EAUs 
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without recent drinking, which are similar to chronic-plus-binge and chronic ethanol feeding 
in mice, respectively. Our data revealed that the serum ALT and AST levels were much 
higher in the EAUs with recent drinking than in those without recent drinking28. These 
results are consistent with the mouse data that chronic-plus-binge feeding induced much 
greater liver damage than chronic ethanol feeding28. Another key feature from the chronic-
plus-binge feeding mouse model is the elevation of circulating and hepatic neutrophils28. 
Remarkably, we also found that circulating neutrophils were highly elevated in EAUs with 
recent drinking, accounting for approximately 80% of the total WBC, which was much 
higher than the numbers in those without recent drinking (approximately 60–67% of total 
WBC)28. Moreover, there was a strong positive correlation between circulating neutrophil 
counts and the serum ALT and AST levels in the EAUs with recent drinking, which 
suggested that excessive drinking likely causes the increase in hepatic neutrophil infiltration 
and liver injury in these subjects. Physicians should pay attention to recent drinking history 
when reviewing complete blood count results from alcoholics. In addition to other known 
causes of neutrophilia such as bacterial infection, a significant elevation of circulating 
neutrophils may indicate recent drinking in these subjects.
Obesity and binge drinking in humans are very common. Recent data that showed that a 
single oral binge exposure to ethanol can trigger acute steatohepatitis in HFD-fed mice 
suggested that binge drinking may cause acute liver injury in obese/overweight individuals 
and that obese individuals should avoid binge drinking on the basis that this would be likely 
to cause significant acute liver damage18. Future prospective cohort studies are urgently 
needed to investigate the effects of acute ethanol binging on liver damage in obese/
overweight individuals.
Perspective
Over the last several years, the addition of ethanol binging to the models of chronically 
ethanol-fed mice or HFD-fed mice has been one of the major advances in the field of ALD 
research. These clinically relevant models induce more severe steatosis, hepatocellular 
damage, and hepatic neutrophil infiltration, compared with the ad libitum chronic ethanol 
feeding models. However, these models still represent only early alcoholic steatohepatitis. 
Long-term chronic feeding and multiple binges of ethanol feeding induce more severe 
steatohepatitis with mild fibrosis than the chronic-plus-one binge ethanol feeding model. 
The model of long-term-HFD-plus-multiple binges of ethanol feeding is challenging to 
establish due to body weight loss and high mortality. The hybrid model developed by Dr. 
Tsukamoto’s group induces much more severe liver damage and hepatic neutrophil 
infiltration. This model involves feeding mice with a Western diet that is high in cholesterol 
and saturated fat plus intragastric alcohol delivery with weekly binges of alcohol and 
represents a model for early alcoholic hepatitis. However, the hybrid model also presents 
technical challenges. In conclusion, the chronic-plus-binge model represents moderate 
alcoholic steatohepatitis, whereas the hybrid model represents severe alcoholic 
steatohepatitis. The HFD-plus-binge model represents acute steatohepatitis caused by fat and 
binge ethanol. All of these models are clinically relevant. Mechanistically, they can be used 
to study the pathogenesis of ALD at different stages or with different severities. 
Therapeutically, they can be used to test compounds or small molecules for the treatment of 
Gao et al. Page 13
Gene Expr. Author manuscript; available in PMC 2017 July 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ALD. Future prospective studies of human subjects with various drinking patterns and their 
interaction with body weight/obesity on the development of ALD are urgently required. 
These studies may help physicians better manage patients with ALD.
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Abbreviations
ABIC score Age, serum Bilirubin, INR, and serum Creatinine score
AH alcoholic hepatitis
ALD alcoholic liver disease
ALT alanine aminotransferase
AST aspartate aminotransferase
CES1 carboxylesterase 1
CIDEC cell death inducing DFFA like effector C
CXCL1 (C-X-C motif) ligand 1
FGF fibroblast growth factor
ER endoplasmic reticulum
FFAs free fatty acids
FSP27 fat-specific protein 27
HFD high-fat diet
MELD model of end stage liver disease
NAFLD nonalcoholic fatty liver disease
NASH nonalcoholic steatohepatitis
OXLAMs oxidized linoleic acid metabolites
PA palmitic acid
PDGFRα platelet-derived growth factor receptor alpha
PPARγ peroxisome proliferation-activated receptor γ
RIP Receptor-interacting protein kinase
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SCD1 Stearoyl-CoA desaturase-1
SIRT1 Sirtuin 1
SHP small heterodimer partner
SYK Spleen tyrosine kinase
TRPV1 transient receptor potential vanilloid 1
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Figure 1. (A) Mortality rate of male C57BL/6J and C57BL/6N mice subjected to chronic ethanol 
feeding
Eight- to twelve-week old male mice were fed the Lieber-Decali diet containing 5% ethanol 
under the room temperature of 72°±2° F. (B) Mortality of male C57BL/6J mice subjected 
to chronic ethanol feeding under different room temperatures. Eight- to twelve-week old 
male C57BL/6J mice were fed the Lieber-Decali diet containing 5% ethanol under different 
room temperatures as indicated. (C) Mortality of male C57BL/6N mice subjected to 
chronic-plus-binge ethanol. Eight- to twelve-week old male C57BL/6J mice were fed the 
Lieber-Decali diet containing 5% ethanol up to 12 weeks, followed by one binge of ethanol 
(5g/kg). Mice were fed under the room temperature of 72°±2° F. The percentage number on 
the top of each bar indicating the corresponding survival rate.
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Figure 2. (A) Mortality rate of male C57BL/6J mice subjected to HFD-plus-multiple binges
Eight- to twelve-week old male mice were fed an HFD diet for 3 months. Then mice 
continued to be fed with HFD for 4 weeks, plus binge ethanol (5 g/kg) twice a week for 4 
weeks. The survival rate of the mice was determined at 24 hours after the gavage. (B) 
Survival rate of male C57BL/6J and C57BL/6N mice subjected to HFD-plus-single 
ethanol binge. Eight- to twelve-week old male C57BL/6J and C57BL/6N mice were fed an 
HFD diet for 3 months and then subjected to one binge of ethanol (5 g/kg). The survival rate 
was determined 24 hours after the gavage and the percentage of survival is shown on the top 
of the bars. (C) Body weight change of male C57BL/6J mice subjected to HFD-plus-
multiple binges. The mice (n=27) were treated as described in panel A and the body weight 
at the time of each gavage was examined and analyzed.
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Figure 3. Multiple mechanisms underlying alcoholic steatohepatitis
Chronic-plus-binge or HFD-plus-binge ethanol consumption induces ER stress, followed by 
activation of the CREBH-N and subsequent upregulation of the predominant form of 
FSP27β. FSP27 interacts with lipid droplet (LD) membrane proteins and subsequently 
promotes LD formation and steatosis. In addition, ethanol promotes FSP27 translocation 
into mitochondria and subsequent mitochondrial injury and hepatocyte death. Ethanol also 
induces ER stress and subsequently produces pro-inflammatory mediators and danger 
associated molecular patterns (DAMPs). Ethanol feeding activates natural killer T (NKT) 
cells to release pro-inflammatory mediators. Ethanol alters gut bacteria and elevates 
pathogen associated molecular patterns (PAMPs). All of these factors lead to hepatic 
neutrophil infiltration and liver inflammation.
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